Elranatamab Efficacy in MagnetisMM-3 Compared with Real-World Control Arms in Triple-Class Refractory Multiple Myeloma - supplementary material

Supplementary Table 1. Most common physician’s choice treatment regimens observed in COTA and FH databases. Supplementary Table 2. Restricted mean survival time comparison of progression-free survival and overall survival between patients receiving elranatamab in the MagnetisMM-3Cohort A and physician’s choice in the COTA real-world external control arm. Supplemental Figure 1. Progression-free survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting. Supplemental Figure 2. Overall survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.